UBS says AstraZeneca can reach 2030 revenue target
UBS analysts said AstraZeneca can meet its 2030 revenue target even if a highly anticipated lung-cancer clinical trial fails, and continue growing afterward.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.